RecruitingPhase 3NCT05078047
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Studying MITF-related melanoma and renal cell carcinoma predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNICANCER
- Principal Investigator
- Gwenaëlle GRAVIS-MESCAM, MDInstitut Paoli Calmettes, Marseille
- Intervention
- Reduced dose intensity of IO(drug)
- Enrollment
- 646 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Institut de cancérologie de l'Ouest, Angers, France
- Clinique Sainte Catherine, Avignon, France
- Centre Hospitalier de la Côte Basque, Bayonne, France
- CHU Besançon, Besançon, France
- CHU Bordeaux - Hôpial Saint André, Bordeaux, France
- CH Boulogne sur Mer, Boulogne-sur-Mer, France
- Centre François Baclesse, Caen, France
- Centre Jean Perrin, Clermont-Ferrand, France
- Centre Hospitalier Intercommunal, Créteil, France
- CHU Henri Mondor, Créteil, France
- Centre Georges François Leclerc, Dijon, France
- GH Mutualiste de Grenoble, Grenoble, France
- CHD Vendée, La Roche-sur-Yon, France
- Centre Oscar Lambret, Lille, France
- Clinique Chenieux, Limoges, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05078047 on ClinicalTrials.govOther trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).Merck Sharp & Dohme LLC
- ACTIVE NOT RECRUITINGPHASE1NCT04707248A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsDaiichi Sankyo
- RECRUITINGNCT05785052Biomarkers of Renal CancerBiorek S.R.L.
- ACTIVE NOT RECRUITINGPHASE1NCT03170960Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsExelixis
- RECRUITINGNCT00001238Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersNational Cancer Institute (NCI)
See all trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome →